Gyre Therapeutics, Inc. (GYRE) P/E Ratio History
UndervaluedTrading at 262.2x vs 5Y avg 349.5x · 53th percentile · Below historical baseline · Data 2007–2025
Loading P/E history...
P/E Ratio Analysis
As of October 22, 2026, Gyre Therapeutics, Inc. (GYRE) trades at a price-to-earnings ratio of 262.2x, with a stock price of $5.90 and trailing twelve-month earnings per share of $-0.17.
The current P/E is 25% below its 5-year average of 349.5x. Over the past five years, GYRE's P/E has ranged from a low of 46.8x to a high of 1078.8x, placing the current valuation at the 53th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.3x, GYRE trades at a 979% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 152.5x.
Relative to the broader market, GYRE commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GYRE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GYRE Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
GYRE P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $15B | 48.8 | 2.12 | -25% | |
| $3B | 8.8 | - | +68% | |
| $2B | 6.3Lowest | 0.61Best | +817% | |
| $8B | 19.2 | - | +1747%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
GYRE Historical P/E Data (2007–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $7.06 | $0.02 | 285.8x | -18% |
| FY2025 Q3 | - | $7.46 | $0.04 | 196.3x | -44% |
| FY2025 Q2 | Jun 30 2025 | $7.35 | $0.01 | 561.1x | +61% |
| FY2025 Q1 | Mar 31 2025 | $7.72 | $0.04 | 172.7x | -51% |
| FY2024 Q4 | - | $12.10 | $0.11 | 106.3x | -70% |
| FY2023 Q3 | Sep 30 2023 | $7.20 | $0.15 | 46.8x | -87% |
| FY2023 Q2 | Jun 30 2023 | $5.25 | $0.05 | 111.5x | -68% |
| FY2023 Q1 | Mar 31 2023 | $3.15 | $0.04 | 73.3x | -79% |
| FY2022 Q4 | Dec 31 2022 | $7.95 | $0.05 | 171.3x | -51% |
| FY2011 Q2 | - | $33185.25 | $36.23 | 916.0x | +162% |
| FY2011 Q1 | - | $41879.25 | $57.59 | 727.2x | +108% |
| FY2010 Q4 | Dec 31 2010 | $41737.50 | $38.69 | 1078.8x | +209% |
| FY2007 Q3 | Sep 30 2007 | $14159.25 | $42.13 | 336.1x | -4% |
| FY2007 Q2 | Jun 30 2007 | $14411.25 | $53.92 | 267.3x | -24% |
| FY2007 Q1 | Mar 31 2007 | $13104.00 | $68.15 | 192.3x | -45% |
Average P/E for displayed period: 349.5x
GYRE Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GYRE — Frequently Asked Questions
Quick answers to the most common questions about buying GYRE stock.
What is GYRE's P/E ratio?
Gyre Therapeutics, Inc. (GYRE) trailing twelve-month P/E ratio is 262.2x, based on TTM diluted EPS of $-0.17. The 5-year average P/E is 349.5x and the historical range spans 46.8x to 1078.8x.
Is GYRE stock overvalued or undervalued?
GYRE trades at 262.2x P/E, below its 5-year average of 349.5x. At the 53th percentile of its historical range (46.8x–1078.8x), the stock is priced at a discount to its own history.
Is GYRE stock expensive?
No, GYRE is not expensive on a historical basis. The current P/E of 262.2x is below the 5-year average of 349.5x and sits at the 53th percentile of its valuation range.
What is GYRE's historical P/E range?
Over the past 5 years, GYRE's P/E ratio has ranged from 46.8x to 1078.8x, with a median of 196.3x and an average of 349.5x. The current P/E of 262.2x places the stock at the 53th percentile of this range. Full historical data spans 2007–2025.
How does GYRE's P/E compare to the S&P 500?
GYRE trades at 262.2x P/E versus the S&P 500 median of 26.2x. The 901% premium to the market typically reflects higher expected earnings growth or quality.
How does GYRE's valuation compare to Healthcare peers?
Gyre Therapeutics, Inc. P/E of 262.2x compares to the Healthcare sector median of 24.3x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is GYRE's PEG ratio?
GYRE PEG ratio is N/A, based on a P/E of 262.2x and EPS growth of -55.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is GYRE's earnings yield?
GYRE earnings yield is 0.38%, the inverse of its 262.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.